Cite
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
MLA
Clowse, Megan, et al. “Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.” Drug Safety, vol. 39, no. 8, Aug. 2016, pp. 755–62. EBSCOhost, https://doi.org/10.1007/s40264-016-0431-z.
APA
Clowse, M., Feldman, S., Isaacs, J., Kimball, A., Strand, V., Warren, R., Xibillé, D., Chen, Y., Frazier, D., Geier, J., Proulx, J., Marren, A., Clowse, M. E. B., Feldman, S. R., Isaacs, J. D., Kimball, A. B., Warren, R. B., & Xibillé, D. (2016). Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety, 39(8), 755–762. https://doi.org/10.1007/s40264-016-0431-z
Chicago
Clowse, Megan, Steven Feldman, John Isaacs, Alexandra Kimball, Vibeke Strand, Richard Warren, Daniel Xibillé, et al. 2016. “Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.” Drug Safety 39 (8): 755–62. doi:10.1007/s40264-016-0431-z.